Crescent Biopharma (CBIO) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 19.5% versus a gain of 11.8%. Crescent Biopharma is the larger company by market cap ($501.1 million vs $478.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | CTNM |
|---|---|---|
| Share price | $13.49 | $12.73 |
| Market cap | $501.11M | $478.92M |
| 1-day change | -0.59% | +0.63% |
| YTD return | +13.74% | +11.37% |
| 1-year return | +19.49% | +11.76% |
| 5-year return | -93.19% | — |
| EPS (TTM) | $-7.63 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $17.79 |
| 52-week low | $8.72 | $8.60 |
| Distance from 52-week high | -50.78% | -28.42% |
| Average volume | 383.95K | 501.08K |
| Shares outstanding | 37.14M | 32.96M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CBIO vs CTNM FAQ
Which is bigger, Crescent Biopharma or Contineum Therapeutics?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $501.11M compared with $478.92M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CBIO or CTNM?
CBIO returned +19.49% over the past 12 months, compared with +11.76% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.